EPIGENOMICS AG SUCCESSFULLY COMPLETES FIRST STEP TOWARDS LUNG CANCER SCREENING TEST DEVELOPMENT

Epigenomics AG, a molecular diagnostics company developing tests based on DNA methylation, announced the successful identification of novel candidate biomarkers in lung cancer. This marks the completion of the first step in Epigenomics' screening test R&D program for this fatal disease. Prime Zone (http://www.primezone.com/newsroom/news.html?d=106321)